Cargando…

Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes

Luspatercept (Reblozyl®) is a newly approved anti‐anemic drug prohibited by the World Anti‐Doping Agency. It promotes erythropoiesis by limiting apoptosis of immature erythroblasts and the risk of misuse by athletes for doping is high. Proposed detection methods have been published recently but only...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchand, Alexandre, Miller, Geoff, Martin, Laurent, Gobbo, Coralie, Crouch, Andre K., Eichner, Daniel, Ericsson, Magnus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Special Issue ‐ Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084338/ https://www.ncbi.nlm.nih.gov/pubmed/35789123 http://dx.doi.org/10.1002/dta.3341

Ejemplares similares

Urinary excretion profile of prednisolone and prednisone after rectal administration: Significance in antidoping analysis
por: Iannella, Loredana, et al.
Publicado: (2022)

A fast screening method for the detection of CERA in dried blood spots
por: Rocca, Angela, et al.
Publicado: (2021)

Football for life versus antidoping for the masses: ethical antidoping issues and solutions based on the extenuating experiences of an elite footballer competing while undergoing treatment for metastatic testicular cancer
por: Weiler, Richard, et al.
Publicado: (2014)

The Influence of Floorball on Hematological Parameters: Consequences in Health Assessment and Antidoping Testing
por: Wedin, Johan O., et al.
Publicado: (2020)

Antidoping programme and biological monitoring before and during the 2014 FIFA World Cup Brazil
por: Baume, Norbert, et al.
Publicado: (2015)

Understanding the complex mechanisms of β(2)-microglobulin amyloid assembly
por: Eichner, Timo, et al.
Publicado: (2011)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Examining the Current and Future Scientific Field of Antidoping: “Cheaters Should Never Win”
por: Faiss, Raphael, et al.
Publicado: (2020)

The design and analysis of vaccine trials for COVID‐19 for the purpose of estimating efficacy
por: Senn, Stephen
Publicado: (2022)

Local administration of icariin contributes to peripheral nerve regeneration and functional recovery
por: Chen, Bo, et al.
Publicado: (2015)

Repurposing without purpose? Early innovation responses to the COVID‐19 crisis: Evidence from clinical trials
por: Hanisch, Marvin, et al.
Publicado: (2021)

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
por: Jackson, Nicholas, et al.
Publicado: (2020)

Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
por: Tinsley-Vance, Sara M., et al.
Publicado: (2023)

Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administration
por: Wheeler, Graham M., et al.
Publicado: (2016)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
por: Musallam, Khaled M., et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020)

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
por: Longo, Filomena, et al.
Publicado: (2023)

Future Developments in Geographical Agent‐Based Models: Challenges and Opportunities
por: Heppenstall, Alison, et al.
Publicado: (2020)

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
por: Chen, Nianhang, et al.
Publicado: (2020)

Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
por: Stefánsson, Bergur V., et al.
Publicado: (2011)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Downregulation of FGF Signaling by Spry4 Overexpression Leads to Shape Impairment, Enamel Irregularities, and Delayed Signaling Center Formation in the Mouse Molar
por: Marangoni, Pauline, et al.
Publicado: (2019)

Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner
por: Loomans, Janneke I, et al.
Publicado: (2018)

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
por: Delanghe, Sigurd, et al.
Publicado: (2022)

The Canadian pork industry and COVID‐19: A year of resilience
por: McEwan, Ken, et al.
Publicado: (2021)

DeshadowGAN: A Deep Learning Approach to Remove Shadows from Optical Coherence Tomography Images
por: Cheong, Haris, et al.
Publicado: (2020)

Procollagen type III amino‐terminal propeptide and insulin‐like growth factor I as biomarkers of growth hormone administration
por: Cowan, David A., et al.
Publicado: (2021)

Taking the strain? Police well-being in the COVID-19 era
por: Newiss, Geoff, et al.
Publicado: (2022)

Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13)C(8)]‐evacetrapib as a tracer
por: Cannady, Ellen A., et al.
Publicado: (2015)

Racial Disparities in Access to Potential COVID‐19 Vaccine Administration Facilities across US States: A Geographic Information Systems Analysis
por: Guo, Jingchuan, et al.
Publicado: (2021)

Auxin‐mediated induction of GAL promoters by conditional degradation of Mig1p improves sesquiterpene production in Saccharomyces cerevisiae with engineered acetyl‐CoA synthesis
por: Hayat, Irfan Farabi, et al.
Publicado: (2021)

Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells
por: Wobus, Manja, et al.
Publicado: (2021)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
por: Delaporta, P., et al.
Publicado: (2022)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
por: Khan, Shamis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2h4bjtvghla1sf06i411qacsla